Cannabimimetic Imidazole Ligands for Selective Fibrosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for fibrosis and inflammatory conditions, such as benign prostatic hyperplasia, often have side effects due to the lack of selective targeting of CB1 and CB2 cannabinoid receptors, and existing compounds do not effectively address these conditions with minimal adverse effects.
Innovation Solution
Development of new cannabimimetic imidazole ligands with specific properties, including CB1 antagonist/CB2 agonist properties and allosteric properties, which can act as neutral antagonists, inverse-agonists, or have mixed properties, selectively targeting CB1 and CB2 receptors to treat fibrosis and inflammatory conditions with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing cannabinoid receptor treatments are used, then therapeutic effects on fibrosis and inflammatory conditions are achieved, but side effects occur due to lack of selective targeting of CB1 and CB2 receptors
Solution Approach 1:
The patent segments the cannabinoid receptor targeting by developing compounds that selectively bind to either CB1 or CB2 receptors, or both with different affinities. This is achieved through specific molecular structures (imidazoles, triazoles, thiazoles, oxazoles, pyrazoles, dihydropyrazoles) designed to interact with particular receptor sites, enabling differentiated therapeutic effects on fibrosis and inflammatory conditions while minimizing off-target side effects
Solution Approach 2:
The patent applies local quality by creating compounds with specific pharmacological properties (neutral antagonists, inverse-agonists, peripheral antagonists, compounds with mixed properties, allosteric modulators) that exert different effects at different receptor locations. This allows tailored therapeutic action - for example, peripheral antagonism for inflammatory conditions while avoiding central psychoactive effects, or selective CB2 agonism for anti-inflammatory effects without CB1-mediated side effects
2Adaptability or versatility
If non-selective cannabinoid receptor antagonists are used, then broad therapeutic coverage is achieved, but adverse effects increase due to lack of selectivity
Solution Approach 1:
The patent employs dynamic pharmacological properties by developing compounds that can function as neutral antagonists, inverse-agonists, or compounds with mixed properties depending on the receptor context and tissue distribution. This dynamic behavior allows the same compound to provide broad therapeutic coverage across different conditions while adapting its effect profile to minimize adverse effects in specific tissue environments
Solution Approach 2:
The patent utilizes parameter changes by modifying molecular structures (varying R1, R2, R3, R4 substituents on the core imidazole/triazole/thiazole/oxazole/pyrazole/dihydropyrazole framework) to precisely tune receptor affinity and selectivity. This enables optimization of the therapeutic window - achieving sufficient binding affinity for effective coverage while reducing affinity for off-target receptors that would cause adverse effects
Data Source
AI summary
Several biological targets have been implicated in the pathogenesis of lung, liver, renal and prostrate fibrotic proliferative diseases. While cannabinoid receptor-mediated signaling has emerged as a novel signaling pathway regulating fibrogenesis and inflammation, the present invention relates generally to biologically active compounds capable of interacting with one or more biological targets including the CB1 and/or the CB2 cannabinoid receptors, and comprise of neutral antagonists, neutral-peripheral antagonists, peripheral antagonists/inverse-agonists, compounds with mixed properties including CB1 antagonist/CB2 agonist properties, and allosteric properties for treating fibrosis of the liver, lung, kidney and the prostrate, and inflammatory conditions, including benign prostatic hyperplasia. Also, aspects of the invention are concerned with imidazoles, triazoles, thiazoles, oxazoles, pyrazoles and dihydropyrazoles containing the 4-(λ2-azaneyl)thiomorpholine 1,1-dioxide group or the 4λ2-thiomorpholine 1,1-dioxide group.